title: A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group.
abstract: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) comprises a group of heterogeneous lymphomas that do not fit any other identified PTCL-subgroup and show poor prognosis. To clarify clinical aspects of Japanese PTCL-NOS patients, the Hokkaido Hematology Study Group conducted a multicenter retrospective analysis. The median age of the 107 patients (male 65.4 %) was 67 years. The majority (82.4 %) had stage III/IV disease. Following the international prognostic index, 65.7 % were categorized as high intermediate or high risk. Primary chemotherapy was selected in 96 (90 %) patients, 86 of whom received anthracycline regimens. Sixteen patients received high-dose chemotherapy with autologous stem cell transplantation. Forty-eight (52 %) of the 92 evaluable patients achieved complete remission (CR) or CR/unconfirmed after the primary treatment, in which 22 (46 %) relapsed. The estimated 5-year overall survival (OS) of all patients was 35 %. Three independent risk factors (RFs) associated with OS, bulky disease (hazard ratio HR = 5.324; p = 0.019), age >60 years (HR = 3.015; p = 0.025), and platelet count less than 10 × 10(4)/μL (HR = 3.999; p = 0.036), were identified in a multivariate analysis. Using these three RFs, the OS curves were significantly stratified into three risk groups (low risk, 0 RFs, 3-year-OS 72 %; intermediate risk, one RF, 30 %; high risk, two or three RFs, 0 %; p = 0.0005). These findings may provide valuable information for the management of Japanese PTCL-NOS patients.
authors.affiliation: Oncology Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Torimoto
authors.forename: Kazuya
authors.initials: K
authors.lastname: Sato
authors.forename: Katsuya
authors.initials: K
authors.lastname: Ikuta
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hayashi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hirayama
authors.forename: Junki
authors.initials: J
authors.lastname: Inamura
authors.forename: Hajime
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kobayashi
authors.forename: Kyuhei
authors.initials: K
authors.lastname: Koda
authors.forename: Mitsutoshi
authors.initials: M
authors.lastname: Kurosawa
authors.forename: Akio
authors.initials: A
authors.lastname: Mori
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ota
authors.forename: Hajime
authors.initials: H
authors.lastname: Sakai
authors.forename: Akio
authors.initials: A
authors.lastname: Shigematsu
authors.forename: Motohiro
authors.initials: M
authors.lastname: Shindo
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Shinzaki
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Takahashi
authors.forename: Rishu
authors.initials: R
authors.lastname: Takimoto
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kohgo
authors.forename: Takashi
authors.initials: T
authors.lastname: Fukuhara
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000009:adverse effects; D044466:Asian People; D064592:Autografts; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan / Q000453:epidemiology; D016411:Lymphoma, T-Cell, Peripheral / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D033581:Stem Cell Transplantation; D015996:Survival Rate
chemical_list: D018943:Anthracyclines